We use big data and artificial intelligence to forecast the stock price of Intellia Therapeutics Inc - NTLA. Our stock price predictions cover a period of 3 months. We cover the US equity market. Parallel Mining Corp (CVE:PAL)’s stock price hit a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.10 and last traded at C$0.10, with a volume.

NTLA Stock News and Research Articles - Intellia Therapeutics : latest news, headlines and research articles. View detailed stock price information for Intellia Therapeutics Inc. [NTLA:US] from TMXmoney including charting and last 25 trades. 11/7/2019 · As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. NTLA. The stock has moved higher by 22.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. Intellia Therapeutics Inc (NASDAQ:NTLA) shares saw unusually-strong trading volume on Friday . Approximately 6,966,576 shares changed hands during trading, an increase of 1,058% from the previous session’s volume of 601,809 shares.The stock last traded at $16.37 and had previously closed at $15.23. The latest closing stock price for Intellia Therapeutics as of December 23, 2019 is 15.82. The all-time high Intellia Therapeutics stock closing price was 34.95 on March 09, 2018. The Intellia Therapeutics 52-week high stock price is 19.00, which is 20.1% above the current share price.

8/1/2019 · Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report

Stocks Analysis by Zacks Investment Research covering: BTC/USD, Intellia Therapeutics Inc. Read Zacks Investment Research's latest article on Investing.com Their average twelve-month price target is $26.92, suggesting that the stock has a possible upside of 83.48%. The high price target for NTLA is $57.50 and the low price target for NTLA is $16.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy." 12/27/2019 · Interactive chart for Intellia Therapeutics, Inc. (NTLA) – analyse all of the data with a huge range of indicators. Chicago, IL - March 13, 2018 - Today, Zacks Investment Ideas feature highlights Features: Sarepta Therapeutics SRPT, bluebird bio BLUE, Editas Medicine EDIT, Align Technology ALGN and Intellia Therapeutics NTLA. Why Sarepta (SRPT) Jumped and We Sold. Monday morning's news from Sarepta Therapeutics Acorda Therapeutics INC . The Morningstar Rating is provided for nasdaq ntla those ETFs with least year history

11/9/2019 · Zacks Investment Research upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a strong-buy rating in a research report released on Wednesday morning, Zacks.com reports. They currently have $15.00 target price on the stock.

Zacks: Analysts Expect Sterling Bancorp (NYSE:STL) Will Post Quarterly Sales of $260.37 Million

12/25/2019 · Has Intellia Therapeutics (NTLA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Intellia Therapeutics is one of 881 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength

Get breaking news and analysis on Intellia Therapeutics, Inc. (NTLA) stock, price quote and chart, trading and investing tools. Stock quote for Intellia Therapeutics, Inc. Common Stock Common Stock (NTLA) with real-time last sale and extended hours stock prices, company news, charts, and Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Zacks 07:30AM Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments GlobeNewswire NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -10.42%.

Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis.

NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Zacks Equity Research 12/25/2019 05:30 AM ET  NTLA | Complete Intellia Therapeutics Inc. stock news by MarketWatch. View real-time stock prices This Year? Dec. 25, 2019 at 11:30 a.m. ET on Zacks.com